Repligen Corporation (RGEN)
NASDAQ
Closed
Aug 24, 2026
Day's Range
176.2852 wk Range
100.99Overview - RGEN - Repligen Corporation
Key Statistics
Valuation
Enterprise Value
10.10B
P/E (Trailing)
‪251.56‬
P/E (Forward)
‪68.63‬
PEG Ratio
‪-3.84‬
Price / Sales (TTM)
‪13.02‬
Price / Book
‪4.83‬
EV / EBITDA
‪70.10‬
Profitability
Gross Margin
‪53.90%‬
Profit Margin
‪5.29%‬
Operating Margin
‪9.30%‬
Return on Assets
‪1.39%‬
Return on Equity
‪1.99%‬
Ownership
Shares Outstanding
56.42M
Float
53.47M
Short % of Shares Outstanding
‪10.90%‬
Held by Insiders
‪5.24%‬
Held by Institutions
‪120.03%‬
Price stats
Beta
‪1.01‬
50-Day Avg
‪146.95‬
200-Day Avg
‪140.61‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
22 analysts
Average price target
‪$ 185.70‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - RGEN - Repligen Corporation
Peers - RGEN - Repligen Corporation
Peer Comparison
Compared with companies in Medical Instruments & Supplies listed on NASDAQ.
Profile Summary - RGEN - Repligen Corporation
About
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to support the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Headquartered in Waltham, Massachusetts, it serves…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
